Cognitive reawakening and improved quality of life achieved after discontinuing 16 years of anti-seizure treatment with topiramate
A 42-year-old female patient with epilepsy and a co-morbid migraine suffered from the severe cognitive side effects of topiramate (TPM) for more than 16 years with detrimental consequences for her daily functioning, career, and social interaction. Even a prodromal stage of dementia was suggested, giving rise to fears of developing a neurodegenerative disease. Recently, cognitive monitoring of attention and executive function before and after withdrawal of TPM revealed a significant recovery from the severe negative cognitive side effects of the long-standing and inefficacious antiseizure medication (ASM). Whereas the side effects were reversible after cessation, their consequences for the patient`s biography were permanent. A considerable increase in quality of life, however, was observed without TPM and family members were impressed by the improvements. This case illustrates the potentially severe consequences of negative cognitive side effects which affect daily functioning, career and social life, thus underscoring the importance of being knowledgeable of the potential cognitive risks when prescribing an ASM. Because cognitive side effects may not depend solely on ASM choice and drug load, but also on individual idiosyncratic intolerances, and patients might stay on their treatment for many years, cognitive monitoring is highly recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Neurocase - 28(2022), 1 vom: 01. Feb., Seite 102-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Witt, Juri-Alexander [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.05.2022 Date Revised 16.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13554794.2022.2032187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336365071 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336365071 | ||
| 003 | DE-627 | ||
| 005 | 20231225231959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13554794.2022.2032187 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336365071 | ||
| 035 | |a (NLM)35102809 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Witt, Juri-Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cognitive reawakening and improved quality of life achieved after discontinuing 16 years of anti-seizure treatment with topiramate |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2022 | ||
| 500 | |a Date Revised 16.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 42-year-old female patient with epilepsy and a co-morbid migraine suffered from the severe cognitive side effects of topiramate (TPM) for more than 16 years with detrimental consequences for her daily functioning, career, and social interaction. Even a prodromal stage of dementia was suggested, giving rise to fears of developing a neurodegenerative disease. Recently, cognitive monitoring of attention and executive function before and after withdrawal of TPM revealed a significant recovery from the severe negative cognitive side effects of the long-standing and inefficacious antiseizure medication (ASM). Whereas the side effects were reversible after cessation, their consequences for the patient`s biography were permanent. A considerable increase in quality of life, however, was observed without TPM and family members were impressed by the improvements. This case illustrates the potentially severe consequences of negative cognitive side effects which affect daily functioning, career and social life, thus underscoring the importance of being knowledgeable of the potential cognitive risks when prescribing an ASM. Because cognitive side effects may not depend solely on ASM choice and drug load, but also on individual idiosyncratic intolerances, and patients might stay on their treatment for many years, cognitive monitoring is highly recommended | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epilepsy | |
| 650 | 4 | |a antiepileptic drugs | |
| 650 | 4 | |a antiseizure drugs | |
| 650 | 4 | |a cognition | |
| 650 | 4 | |a cognitive decline | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a neuropsychology | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a side effects | |
| 650 | 4 | |a withdrawal | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Topiramate |2 NLM | |
| 650 | 7 | |a 0H73WJJ391 |2 NLM | |
| 650 | 7 | |a Fructose |2 NLM | |
| 650 | 7 | |a 30237-26-4 |2 NLM | |
| 700 | 1 | |a Rademacher, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a von Wrede, Randi |e verfasserin |4 aut | |
| 700 | 1 | |a Surges, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Helmstaedter, Christoph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurocase |d 1997 |g 28(2022), 1 vom: 01. Feb., Seite 102-106 |w (DE-627)NLM094530270 |x 1465-3656 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:1 |g day:01 |g month:02 |g pages:102-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13554794.2022.2032187 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 1 |b 01 |c 02 |h 102-106 | ||